Business
Isodiol International Inc Provides an Update on the Delay in Filing Its Audited Financial Statements
Isodiol International Inc Provides an Update on the Delay in Filing Its Audited Financial Statements.
About this update from Isodiol International Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), provides an update on the delay on the filing of its audited annual financial statements, related management’s discussion and analysis and supporting officer certificates for the financial year ended March 31, 2019 (the “Filings”). \n The Company obtained a management cease trade order dated July 30, 2019 from the relevant securities regulators as contemplated by National Policy 12-203 Management Cease Trade Orders of the Canadian Securities Administrators. The delay of the Filings resulted from delays in the Company obtaining access to accounting information following dispositions of subsidiaries over which the Company no longer has management influence.  The Company notes the audit is nearly complete and continues to expect to file the Filings on or before August 16, 2019. The Company will comply with the requirements of the alternative information guidelines set out in the National Policy.   The Company is not subject to any insolvency proceedings. Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol. About Isodiol International Inc. Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe. ON BEHALF OF THE BOARD Marcos Agramont, CEO & Director INVESTOR RELATIONS:[email protected] MEDIA CONTACT:Christopher [email protected] The CSE has not reviewed, approved or disapproved the content of this press release. Forward-Looking Information: This news release contains \"forward-looking information\" within the meaning of applicabl...